Coca-Cola has struggled to integrate its $5.6 billion purchase of BodyArmor with Powerade, which led to more “disruption in the short-term” than expected, according to CEO James Quincey.
Body Armor’s sales declined in the latest quarter.
The Atlanta-based Coca-Cola is optimistic that BodyArmor will eventually complement Powerade, its other big offering in the sports-drink category, as it aims to better compete against industry heavyweight, Pepsi-owned Gatorade.
BodyArmor’s purchase is the largest acquisition in Coca-Cola’s history.
In 2018, Coca-Cola first paid an undisclosed sum for a 15% share in BodyArmor, which had revenues of around $250 million.
That amount increased to more than $1 billion in 2021 when it acquired the remaining shares of brand to increase the variety of beverages it offers.
Through the use of coconut water, low sodium and high potassium levels, the lack of artificial colors, and the addition of sugar in place of high fructose corn syrup, the fast-growing, healthier sports drink gained popularity among consumers.
The purchase of BodyArmor by Coca-Cola led to a big bet that the beverage would play a key role in building out its liquid offerings and repositioning the business into a “total beverage company.”
Coca-Cola’s U.S. sports-drink market share had slipped in recent months. Still, the Coke chief remains optimistic this year will be a turning point for BodyArmor.


Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Champions League final 2025: a battle for glory against a backdrop of money and fashion
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
From Messi to Mika Häkkinen: how top athletes can slow down time
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Trump Attends Super Bowl Amid Cheers, Boos, and Political Divide
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 



